BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

561 related articles for article (PubMed ID: 33477020)

  • 1. Design, synthesis and biological evaluation of novel indanone containing spiroisoxazoline derivatives with selective COX-2 inhibition as anticancer agents.
    Abolhasani H; Zarghi A; Komeili Movahhed T; Abolhasani A; Daraei B; Dastmalchi S
    Bioorg Med Chem; 2021 Feb; 32():115960. PubMed ID: 33477020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New Ferrocene Compounds as Selective Cyclooxygenase (COX-2) Inhibitors: Design, Synthesis, Cytotoxicity and Enzyme-inhibitory Activity.
    Farzaneh S; Zeinalzadeh E; Daraei B; Shahhosseini S; Zarghi A
    Anticancer Agents Med Chem; 2018; 18(2):295-301. PubMed ID: 28971779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New oxadiazoles with selective-COX-2 and EGFR dual inhibitory activity: Design, synthesis, cytotoxicity evaluation and in silico studies.
    El-Sayed NA; Nour MS; Salem MA; Arafa RK
    Eur J Med Chem; 2019 Dec; 183():111693. PubMed ID: 31539778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New 1,2,4-triazole/pyrazole hybrids linked to oxime moiety as nitric oxide donor celecoxib analogs: Synthesis, cyclooxygenase inhibition anti-inflammatory, ulcerogenicity, anti-proliferative activities, apoptosis, molecular modeling and nitric oxide release studies.
    Fadaly WAA; Elshaier YAMM; Hassanein EHM; Abdellatif KRA
    Bioorg Chem; 2020 May; 98():103752. PubMed ID: 32197148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New nimesulide derivatives with amide/sulfonamide moieties: Selective COX-2 inhibition and antitumor effects.
    Güngör T; Ozleyen A; Yılmaz YB; Siyah P; Ay M; Durdağı S; Tumer TB
    Eur J Med Chem; 2021 Oct; 221():113566. PubMed ID: 34077833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Indomethacin based new triazolothiadiazine derivatives: Synthesis, evaluation of their anticancer effects on T98 human glioma cell line related to COX-2 inhibition and docking studies.
    Sever B; Altıntop MD; Kuş G; Özkurt M; Özdemir A; Kaplancıklı ZA
    Eur J Med Chem; 2016 May; 113():179-86. PubMed ID: 26927686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and Evaluation of a New Series of Arylidene Indanones as Potential Anticancer Agents.
    Özdemir A; Gökbulut S; Sever B; Çiftçi GA; Altıntop MD
    Anticancer Agents Med Chem; 2018; 18(10):1394-1404. PubMed ID: 29210665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and Biological Evaluation of 1,3,5-Trisubstituted 2-Pyrazolines as Novel Cyclooxygenase-2 Inhibitors with Antiproliferative Activity.
    Vahedpour T; Kaur J; Hemmati S; Hamzeh-Mivehroud M; Alizadeh AA; Wuest F; Dastmalchi S
    Chem Biodivers; 2021 Mar; 18(3):e2000832. PubMed ID: 33620122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and evaluation of novel diaryl-1,5-diazoles derivatives bearing morpholine as potent dual COX-2/5-LOX inhibitors and antitumor agents.
    Li Z; Wang ZC; Li X; Abbas M; Wu SY; Ren SZ; Liu QX; Liu Y; Chen PW; Duan YT; Lv PC; Zhu HL
    Eur J Med Chem; 2019 May; 169():168-184. PubMed ID: 30877972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, Synthesis, Docking Studies, Enzyme Inhibitory and Antiplatelet Aggregation Activities of New 1,3-Diphenyl-3-(Phenylthio)Propan-1-One Derivatives as Selective COX-2 Inhibitors.
    Bayanati M; Daraei B; Zarghi A
    Anticancer Agents Med Chem; 2023; 23(2):192-200. PubMed ID: 35692149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and biological evaluation of novel hybrids of 1, 5-diarylpyrazole and Chrysin for selective COX-2 inhibition.
    Ren SZ; Wang ZC; Zhu XH; Zhu D; Li Z; Shen FQ; Duan YT; Cao H; Zhao J; Zhu HL
    Bioorg Med Chem; 2018 Aug; 26(14):4264-4275. PubMed ID: 30031652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of novel aminophosphonate derivatives containing pyrazole moiety as potential selective COX-2 inhibitors.
    Zhang B; Hu XT; Zhou KM; Yang YS; Zhu HL
    Bioorg Chem; 2020 Sep; 102():104096. PubMed ID: 32707279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of novel sulfonamide-containing aminophosphonate derivatives as selective COX-2 inhibitors and anti-tumor candidates.
    Zhang B; Hu XT; Gu J; Yang YS; Duan YT; Zhu HL
    Bioorg Chem; 2020 Dec; 105():104390. PubMed ID: 33137555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, and biological evaluation of new 1,4-diarylazetidin-2-one derivatives (β-lactams) as selective cyclooxygenase-2 inhibitors.
    Arefi H; Naderi N; Shemirani ABI; Kiani Falavarjani M; Azami Movahed M; Zarghi A
    Arch Pharm (Weinheim); 2020 Mar; 353(3):e1900293. PubMed ID: 31917485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, Synthesis,
    Ahmadi N; Khoramjouy M; Movahed MA; Amidi S; Faizi M; Zarghi A
    Anticancer Agents Med Chem; 2024; 24(7):504-513. PubMed ID: 38275051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploration of isoxazole analogs: Synthesis, COX inhibition, anticancer screening, 3D multicellular tumor spheroids, and molecular modeling.
    Hawash M; Abdallah S; Abudayyak M; Melhem Y; Abu Shamat M; Aghbar M; Çapan I; Abualhasan M; Kumar A; Kamiński M; Góral T; Dominiak PM; Sobuh S
    Eur J Med Chem; 2024 May; 271():116397. PubMed ID: 38626522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Thiourea Derivatives Bearing Sulfonamide Moiety as Anticancer Agents Through COX-2 Inhibition.
    Ghorab MM; El-Gaby MSA; Alsaid MS; Elshaier YAMM; Soliman AM; El-Senduny FF; Badria FA; Sherif AYA
    Anticancer Agents Med Chem; 2017; 17(10):1411-1425. PubMed ID: 28356021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, and biologic evaluation of novel chrysin derivatives as cytotoxic agents and caspase-3/7 activators.
    Al-Oudat BA; Alqudah MA; Audat SA; Al-Balas QA; El-Elimat T; Hassan MA; Frhat IN; Azaizeh MM
    Drug Des Devel Ther; 2019; 13():423-433. PubMed ID: 30774307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, and biological evaluation of new pyrazino[1,2-a]benzimidazole derivatives as selective cyclooxygenase (COX-2) inhibitors.
    Azami Movahed M; Daraei B; Shahosseini S; Esfahanizadeh M; Zarghi A
    Arch Pharm (Weinheim); 2019 Feb; 352(2):e1800265. PubMed ID: 30561073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis and biological evaluation of novel ferrocene-pyrazole derivatives containing nitric oxide donors as COX-2 inhibitors for cancer therapy.
    Ren SZ; Wang ZC; Zhu D; Zhu XH; Shen FQ; Wu SY; Chen JJ; Xu C; Zhu HL
    Eur J Med Chem; 2018 Sep; 157():909-924. PubMed ID: 30149323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.